Arana gains development partner for cancer program
Australia's Arana Therapeutics has struck a deal to co-develop an experimental colorectal cancer therapy with Japan's Kyowa Hakko Kogyo. Arana will receive up to $8 million in the joint venture and the two companies will split ownership of ART104. The developers will split the development costs, with the Japanese company contributing technology to the program. Kyowa has rights to commercialize the therapy in some Asian markets.
- see the release
- check out the report from AFX
Related Articles:
Amgen inks $520M deal with Kyowa Hakko
Kyowa Hakko receives not approvable letter
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets